회원가입 | 연락처 | 사이트맵 | English

      회사소개 | 리포트 | 커스텀 리서치 | 고객지원


로그인

카테고리

유/무선통신

전기/전자

디지털기기/미디어/방송

Information Technology

에너지

생명공학

화학/신소재

자동차

환경

일반소비재

마케팅/광고

금융

건설

교통/운송

소비자조사

방위/항공/우주

식음료

중공업

교육

기계

무역

스포츠/레저

해운/조선

패션

정부/정책

공예/귀금속

컴퍼니 프로파일

기타산업

 
현재위치 : HOME > 리포트 > 생명공학 > 제약
Investigation Report on China Capecitabine Market, 2010-2019
발행사 China Research and Intelligence

발행일 2015-06
분량 30 pages
서비스형태 Report
판매가격

인쇄하기

Description

Capecitabine, developed by F. Hoffmann-La Roche Ltd, entered the markets in the US, Canada and Sweden in 1998 under the trade name of Xeloda and then spread through over 80 countries and regions in 2 years. In Mar. 2001, capecitabine entered China to be clinically used for the treatment of advanced breast cancer, colorectal cancer and other solid tumors. The chemotherapy for colorectal cancer has mainly relied on traditional cytotoxic drugs for years. Capecitabine, as orally-administered tablets, acts directly in intestine and drug concentration in the tumor tissues is higher than that in blood. Besides, it features flexible dose adjustments and compliant method of administration. All this has contributed to its market growth.
Capecitabine develops fast after entering China, annual sales value rising from less than CNY 100 million in 2005 to CNY 635 million in 2014 and CAGR reaching up to 25.3% during this period. Capecitabine enjoys a vast demand in China. Currently, there are mainly five manufacturers of capecitabine in China: Shanghai Roche Pharmaceutical Co., Ltd, Qilu Pharmaceutical Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd and Chia Tai Tianqing Pharmaceutical Group Co., Ltd, among which Shanghai Roche Pharmaceutical Co., Ltd has the largest market share of over 95% with sales value exceeding CNY 600 million in 2014.
With the degradation of environment and lifestyle changes brought about by improved living standards, the incidence of cancer keeps increasing in China. Therefore, capecitabine has good prospects in China and its market size will keep growing.

Readers can get at least the following information from this report:

-market share of manufacturers of capecitabine in China
-price of capecitabine in Chinese market
-major manufacturers of capecitabine in Chinese market
-share of dosage forms of capecitabine in China
-market outlook of capecitabine in China

The author suggests the following groups of people purchase this report:

-manufacturers of antitumor drugs
-investors/ research institutions interested in Chinese medicine market
-any interest in the Chinese medicine market, please contact CRI for customized survey service


회사소개 | 개인정보보호정책 | 이용약관 | 배송/결제안내 | 이용안내

서울시 강남구 논현동 210-1 삼원빌딩 | 회사명 : (주)엘앤에치
대표전화 : 02-554-0001 / 팩스 : 02-3444-5501 / 이메일 : sales@landh.co.kr
Copyright ⓒ 2008 LNH, Inc. All rights reserved.